These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32038986)

  • 1. The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas.
    Liu S; Zhu Y; Zhang C; Meng X; Sun B; Zhang G; Fan Y; Kang X
    Front Oncol; 2020; 10():9. PubMed ID: 32038986
    [No Abstract]   [Full Text] [Related]  

  • 2. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
    Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
    Front Immunol; 2020; 11():580335. PubMed ID: 33224142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome.
    Li S; Yi L; Wei X; Zhang J; Wang X; Jiang C; Yan Z; Song L; Yang B; Wei P; Gao X; Wang J; Zhang H; Zhang J
    Front Cardiovasc Med; 2022; 9():971414. PubMed ID: 36119741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients.
    Liu S; Zhu Y; Zhang C; Liu J; Lv H; Zhang G; Kang X
    J Med Biochem; 2020 Oct; 39(4):444-451. PubMed ID: 33312060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.
    Cheng CL; Yao CY; Huang PH; Yu CW; Fang WQ; Chuang WH; Wu SJ; Lin YJ; Hung YC; Tsai CH; Yu SC; Chou WC; Tien HF
    Br J Haematol; 2023 Apr; 201(1):75-85. PubMed ID: 36480431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer.
    Sun J; Qiu MZ; Mei T; Gao Y; Chang B; Zhang Y; Wang FH; Li S
    Transl Cancer Res; 2020 Apr; 9(4):2434-2448. PubMed ID: 35117603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity.
    Du Y; Nie L; Xu L; Wu X; Zhang S; Xue J
    Scand J Immunol; 2020 Jul; 92(1):e12884. PubMed ID: 32243638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer.
    Kruger S; Legenstein ML; Rösgen V; Haas M; Modest DP; Westphalen CB; Ormanns S; Kirchner T; Heinemann V; Holdenrieder S; Boeck S
    Oncoimmunology; 2017; 6(5):e1310358. PubMed ID: 28638732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma.
    Guo X; Wang J; Jin J; Chen H; Zhen Z; Jiang W; Lin T; Huang H; Xia Z; Sun X
    Transl Oncol; 2018 Jun; 11(3):779-785. PubMed ID: 29698935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M
    PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
    Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
    Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
    Luo L; Shu M; Li S; Cai Y
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
    Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
    Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications].
    Zhang LQ; Chen Y; Pan X; Xing YF; Shi MH; Chen YJ
    Zhonghua Yi Xue Za Zhi; 2016 Dec; 96(48):3870-3874. PubMed ID: 28057155
    [No Abstract]   [Full Text] [Related]  

  • 16. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
    [No Abstract]   [Full Text] [Related]  

  • 17. Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer.
    Aghajani MJ; Roberts TL; Yang T; McCafferty CE; Caixeiro NJ; DeSouza P; Niles N
    Endocr Connect; 2019 Jul; 8(7):1040-1051. PubMed ID: 31252406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours.
    Mair MJ; Pajenda S; Ilhan-Mutlu A; Steindl A; Kiesel B; Widhalm G; Dieckmann K; Feldmann K; Hainfellner J; Marosi C; Müllauer L; Wagner L; Preusser M; Berghoff AS
    ESMO Open; 2020 Nov; 5(6):e000863. PubMed ID: 33184096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. sPD-L1 Expression is Associated with Immunosuppression and Infectious Complications in Patients with Acute Pancreatitis.
    Chen Y; Li M; Liu J; Pan T; Zhou T; Liu Z; Tan R; Wang X; Tian L; Chen E; Qu H
    Scand J Immunol; 2017 Aug; 86(2):100-106. PubMed ID: 28513984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.